

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Upadacitinib for treating giant cell arteritis [ID6299]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<p>Yes, stakeholders highlighted that there are limited treatment options and inequality of treatment provisions across England for giant cell arteritis.</p>

<p>This condition mainly effects elderly people, who are at risk of side effects of long-term use of corticosteroids leading to disability</p>

<p>A current treatment tocilizumab is prescribed in specialist centres and older people living in rural areas, frailer people or people with disabilities may face challenges accessing specialised centres.</p>

- | | |
|----|------------------------------------------------------------------------------------------------------------------|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|------------------------------------------------------------------------------------------------------------------|

<p>Issues of differences in disease prevalence cannot be addressed in a technology evaluation. However, the committee will consider carefully the needs of the people who would have upadacitinib in clinical practice and if its recommendations make access to the therapy more difficult for certain groups.</p>

- | | |
|----|---------------------------------------------------------------------------------------|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---------------------------------------------------------------------------------------|

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

N/A

Approved by Associate Director (name): Lorna Dunning

Date: 12/03/25